NSRX

Nasus Pharma Ltd.

AMEX: NSRX · HEALTHCARE · DRUG MANUFACTURERS - GENERAL

$3.07

-3.76% today

Updated 2026-10-30

Market cap

$40.88M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.20

Dividend yield

—

52W range

$2 – $10

Volume

0.0M

Market cap

$40.88M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.20

Dividend yield

—

52W range

$2 – $10

Volume

0.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.0

Quality

B+

3.5

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

-7.0

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →256 stocks currently score above 75

Price targets

Analyst target

$19.67

+540.72%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Altman Z -7.03 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-1.99M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	—
Net income	$-1.71M	$-1.05M	$-1.53M	$-5.86M	$-5.94M
EPS	—	—	—	—	$-1.20
Free cash flow	$-1.21M	$-1.03M	$-665000.00	$-4.93M	$-1.99M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NSRX	$40.88M	20	4.3	3.5	5.0	7.0	—	Avoid
LLY	$1.12T	76	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$615.87B	57	4.7	8.5	2.7	5.5	-83.05%	Buy
ABBV	$504.37B	73	6.7	8.5	4.0	5.0	-86.73%	Strong Buy
UNH	$360.32B	62	6.7	6.0	4.7	5.5	-25.92%	Buy
MRK	$360.08B	36	4.0	4.5	2.0	5.0	-73.68%	Hold

Smart narrative

Nasus Pharma Ltd. trades at $3.07. Our Smart Value Score of 20/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -7.03, it sits in the distress.

Frequently asked questions

What is Nasus Pharma Ltd.'s stock price?

Nasus Pharma Ltd. (NSRX) trades at $3.07.

Is Nasus Pharma Ltd. overvalued?

Nasus Pharma Ltd. carries a Smart Value Score of 20/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Nasus Pharma Ltd. (NSRX)?

The 12-month analyst consensus target is $19.67, about 540.7% above the current $3.07. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Nasus Pharma Ltd.'s Altman Z-Score is -7.03, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - GENERAL

CountryUSA

ExchangeAMEX

CurrencyUSD

Quick metrics

P/S ratio—

ROE—

Beta—

50D MA$3.62

200D MA$3.74

Shares out0.01B

Float0.01B

Short ratio—

Avg volume0.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

NSRX vs LLY →NSRX vs JNJ →NSRX vs ABBV →Stock screener →